About this document

LCD Title by AdiaCostas is a document available to read on EtoBox.

This document outlines the limited coverage policy for pharmacogenomics testing (PGx) under Medicare, detailing the indications, limitations, and requirements for coverage. PGx testing is deemed reasonable and necessary when it aids in personalized medication decisions based on gene-drug interactions, and must demonstrate analytical and clinical validity. Specific documentation and clinical context are required to ensure the tests ordered are appropriate for the patient

Author

AdiaCostas

Language

EN